The differential regulation of placenta trophoblast bisphosphoglycerate mutase in fetal growth restriction: preclinical study in mice and observational histological study of human placenta

Abstract

Background: Fetal growth restriction (FGR) is a pregnancy complication in which a newborn fails to achieve its growth potential, increasing the risk of perinatal morbidity and mortality. Chronic maternal gestational hypoxia, as well as placental insufficiency are associated with increased FGR incidence; however, the molecular mechanisms underlying FGR remain unknown.

Methods: Pregnant mice were subjected to acute or chronic hypoxia (12.5% O2) resulting in reduced fetal weight. Placenta oxygen transport was assessed by blood oxygenation level dependent (BOLD) contrast magnetic resonance imaging (MRI). The placentae were analyzed via immunohistochemistry and in situ hybridization. Human placentae were selected from FGR and matched controls and analyzed by immunohistochemistry (IHC). Maternal and cord sera were analyzed by mass spectrometry.

Results: We show that murine acute and chronic gestational hypoxia recapitulates FGR phenotype and affects placental structure and morphology. Gestational hypoxia decreased labyrinth area, increased the incidence of red blood cells (RBCs) in the labyrinth while expanding the placental spiral arteries (SpA) diameter. Hypoxic placentae exhibited higher hemoglobin-oxygen affinity compared to the control. Placental abundance of Bisphosphoglycerate mutase (BPGM) was upregulated in the syncytiotrophoblast and spiral artery trophoblast cells (SpA TGCs) in the murine gestational hypoxia groups compared to the control. Hif1a levels were higher in the acute hypoxia group compared to the control. In contrast, human FGR placentae exhibited reduced BPGM levels in the syncytiotrophoblast layer compared to placentae from healthy uncomplicated pregnancies. Levels of 2,3 BPG, the product of BPGM, were lower in cord serum of human FGR placentae compared to control. Polar expression of BPGM, was found in both human and mouse placentae syncytiotrophoblast, with higher expression facing the maternal circulation. Moreover, in the murine SpA TGCs expression of BPGM was concentrated exclusively in the apical cell side, in direct proximity to the maternal circulation.

Conclusions: This study suggests a possible involvement of placental BPGM in maternal-fetal oxygen transfer, and in the pathophysiology of FGR.

Funding: This work was supported by the Weizmann Krenter Foundation and the Weizmann - Ichilov (Tel Aviv Sourasky Medical Center) Collaborative Grant in Biomedical Research, and by the Minerva Foundation (to MN), by the ISF KillCorona grant 3777/19 (to MN, MK).

Data availability

Source data is available at https://www.ebi.ac.uk/biostudies/bioimages/studies/S-BIAD1030

The following data sets were generated

Article and author information

Author details

  1. Sima Stroganov 

    Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel
    Competing interests
    No competing interests declared.
  2.  Talia   Harris 

    Department of Chemical Research Support, Weizmann Institute of Science, Rehovot, Israel
    Competing interests
    No competing interests declared.
  3.  Liat   Fellus-Alyagor 

    Department of Veterinary Resources, Weizmann Institute of Science, Rehovot, Israel
    Competing interests
    No competing interests declared.
  4. Lital  Ben Moyal 

    Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel
    Competing interests
    No competing interests declared.
  5.  Romina   Plitman Mayo 

    Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel
    Competing interests
    No competing interests declared.
  6. Ofra Golani

    Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9793-236X
  7. Dana Hirsch

    Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel
    Competing interests
    No competing interests declared.
  8. Shifra Ben-Dor

    Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9604-1939
  9. Alexander  Brandis 

    Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel
    Competing interests
    No competing interests declared.
  10.  Tevie   Mehlman 

    Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel
    Competing interests
    No competing interests declared.
  11.  Michal   Kovo 

    Meir Medical Center, Tel Aviv University, Tel Aviv, Israel
    Competing interests
     Michal   Kovo , is the Head of the Israel Society for Maternal Fetal Medicine (ISMFM). The author has no other competing interests to declare..
  12. Tal  Biron-Shental 

    Meir Medical Center, Tel Aviv University, Tel Aviv, Israel
    Competing interests
    Tal  Biron-Shental , is the Head of the Israel Society for Maternal Fetal Medicine (ISMFM). The author has no other competing interests to declare..
  13. Nava Dekel

    Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel
    Competing interests
    No competing interests declared.
  14. Michal Neeman

    Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel
    For correspondence
    michal.neeman@Weizmann.ac.il
    Competing interests
    Michal Neeman, Michal Neeman has received the Killcorona grant from the Israel Science Foundation and the Collaborative Grant in Biomedical Research from Weizmann - Ichilov. The author is also the elected President of European Society of Molecular Imaging. The author has no other competing interests to declare..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6296-816X

Funding

Israel Science Foundation (3777/19)

  •  Michal   Kovo 
  • Michal Neeman

Minerva Foundation

  • Michal Neeman

Weizmann Institute of Science

  • Michal Neeman

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: The studies were approved by the Weizmann Institute IACUC (protocols (Protocols: # 07341021-2, 04170521-2)

Human subjects: Informed consent was obtainedThe study was approved by the Helsinki committees at the Meir and Wolfson Medical Centers (Protocols: # 0147-20 MMC and #185-19-WOMC).

Copyright

© 2024, Stroganov  et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 834
    views
  • 109
    downloads
  • 0
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Sima Stroganov 
  2.  Talia   Harris 
  3.  Liat   Fellus-Alyagor 
  4. Lital  Ben Moyal 
  5.  Romina   Plitman Mayo 
  6. Ofra Golani
  7. Dana Hirsch
  8. Shifra Ben-Dor
  9. Alexander  Brandis 
  10.  Tevie   Mehlman 
  11.  Michal   Kovo 
  12. Tal  Biron-Shental 
  13. Nava Dekel
  14. Michal Neeman
(2024)
The differential regulation of placenta trophoblast bisphosphoglycerate mutase in fetal growth restriction: preclinical study in mice and observational histological study of human placenta
eLife 13:e82631.
https://doi.org/10.7554/eLife.82631

Share this article

https://doi.org/10.7554/eLife.82631

Further reading

    1. Biochemistry and Chemical Biology
    Jianheng Fox Liu, Ben R Hawley ... Samie R Jaffrey
    Tools and Resources

    N 6,2’-O-dimethyladenosine (m6Am) is a modified nucleotide located at the first transcribed position in mRNA and snRNA that is essential for diverse physiological processes. m6Am mapping methods assume each gene uses a single start nucleotide. However, gene transcription usually involves multiple start sites, generating numerous 5’ isoforms. Thus, gene-level annotations cannot capture the diversity of m6Am modification in the transcriptome. Here, we describe CROWN-seq, which simultaneously identifies transcription-start nucleotides and quantifies m6Am stoichiometry for each 5’ isoform that initiates with adenosine. Using CROWN-seq, we map the m6Am landscape in nine human cell lines. Our findings reveal that m6Am is nearly always a high stoichiometry modification, with only a small subset of cellular mRNAs showing lower m6Am stoichiometry. We find that m6Am is associated with increased transcript expression and provide evidence that m6Am may be linked to transcription initiation associated with specific promoter sequences and initiation mechanisms. These data suggest a potential new function for m6Am in influencing transcription.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Eva Herdering, Tristan Reif-Trauttmansdorff ... Ruth Anne Schmitz
    Research Article

    Glutamine synthetases (GS) are central enzymes essential for the nitrogen metabolism across all domains of life. Consequently, they have been extensively studied for more than half a century. Based on the ATP-dependent ammonium assimilation generating glutamine, GS expression and activity are strictly regulated in all organisms. In the methanogenic archaeon Methanosarcina mazei, it has been shown that the metabolite 2-oxoglutarate (2-OG) directly induces the GS activity. Besides, modulation of the activity by interaction with small proteins (GlnK1 and sP26) has been reported. Here, we show that the strong activation of M. mazei GS (GlnA1) by 2-OG is based on the 2-OG dependent dodecamer assembly of GlnA1 by using mass photometry (MP) and single particle cryo-electron microscopy (cryo-EM) analysis of purified strep-tagged GlnA1. The dodecamer assembly from dimers occurred without any detectable intermediate oligomeric state and was not affected in the presence of GlnK1. The 2.39 Å cryo-EM structure of the dodecameric complex in the presence of 12.5 mM 2-OG demonstrated that 2-OG is binding between two monomers. Thereby, 2-OG appears to induce the dodecameric assembly in a cooperative way. Furthermore, the active site is primed by an allosteric interaction cascade caused by 2-OG-binding towards an adaption of an open active state conformation. In the presence of additional glutamine, strong feedback inhibition of GS activity was observed. Since glutamine dependent disassembly of the dodecamer was excluded by MP, feedback inhibition most likely relies on the binding of glutamine to the catalytic site. Based on our findings, we propose that under nitrogen limitation the induction of M. mazei GS into a catalytically active dodecamer is not affected by GlnK1 and crucially depends on the presence of 2-OG.